Sugammadex Review: Has Merck Finally Put Safety Concerns To Rest?
This article was originally published in The Pink Sheet Daily
Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.
You may also be interested in...
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
Advisory committee suggests post-marketing epidemiological studies in higher risk patients to further assess risks of hypersensitivity, anaphylaxis and cardiac rhythm disorders with the neuromuscular blockade reversal agent.
Safety concerns render anesthesia injection “not approvable” in U.S.